BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, May 19, 2026
Breaking News: Bundibugyo is harsh reminder of need for broad vaccine strategiesBreaking News: Tracking hantavirus across the globeBreaking News: Tracking hantavirus across the globe
Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
BioWorld Science, Neurology/psychiatric RSS Feed RSS

Central nervous system
Neurology/Psychiatric

RF-3286: an NPFFR1 antagonist that shows promise for opioid-induced hyperalgesia

Sep. 19, 2022
Neuropeptide FF receptor 1 (NPFFR1) and NPFFR2 regulate several biological functions and there is a lack of blockers for these receptors that allow the study of their function. Université de Strasbourg researchers have presented details on the design of RF-3286, an NPFFR1 antagonist for the potential treatment of hyperalgesia.
Read More
Neurology/Psychiatric

Avicanna collaborates with University of Toronto to advance epilepsy research

Sep. 16, 2022
Avicanna Inc. has expanded its research in the field of epilepsy through a new collaboration with the University of Toronto to explore the efficacy of Avicanna's proprietary formulations in preclinical models of epilepsy.
Read More
Illustration of brain between man and woman
Cancer

Sex differences in brain tumor metabolism suggest the need to adapt treatments

Sep. 16, 2022
By Mar de Miguel
Sex differences at the cellular level could explain why men respond less well to glioblastoma (GBM) treatments, according to a study led by the Washington University School of Medicine in St. Louis (WUSTL). The researchers found that male and female GBM tumor cells had different metabolic needs. GBM cells from male surgical samples absorbed more glutamine and had different nutritional preferences for amino acids.
Read More
Neurology/Psychiatric

Monash University describes efforts to identify new muscarinic acetylcholine receptor PAMs

Sep. 15, 2022
Research at Monash University has led to the identification of structurally novel muscarinic acetylcholine receptor (mAChR) positive allosteric modulators (PAMs) with potential utility in treating Alzheimer's disease and other cognition disorders.
Read More
Antibodies
Neurology/Psychiatric

Novel antibody protects from HML-2 Env-mediated neurotoxicity

Sep. 15, 2022
Human endogenous retrovirus-K (HERV-K) belongs to the β-retrovirus-like supergroup of viruses, and it has been previously demonstrated that the expression of HERV-K subtype HML-2 envelope (Env) in human neuronal cultures or in transgenic mice resulted in neurotoxicity and neurodegeneration.
Read More
Pill over molecule structures
Neurology/Psychiatric

WLB-83038, a small-molecule candidate with new dual mode of action to treat pain

Sep. 15, 2022
Researchers from Welab Barcelona presented the discovery and preclinical evaluation of novel analgesic candidates with a dual mode of action.
Read More
Drug Design, Drug Delivery & Technologies

Combination strategy enables brain-specific kinase inhibition

Sep. 15, 2022
By Anette Breindl
Using a two-drug combination, researchers at the University of California at San Francisco (UCSF) have been able to achieve brain-specific inhibition of several kinases.
Read More
Neurology/Psychiatric

Biohaven Therapeutics identifies TDP43-targeting compounds for neurologic disorders

Sep. 14, 2022
Biohaven Therapeutics Ltd. has divulged compounds targeting TAR DNA-binding protein 43 (TDP43) reported to be useful for the treatment of amyotrophic lateral sclerosis, traumatic encephalopathy, sporadic inclusion body myositis, frontotemporal dementia and Alzheimer's disease.
Read More
Neurology/Psychiatric

Nacuity and Arctic Therapeutics partner on NPI-001 for hereditary cystatin C amyloid angiopathy

Sep. 14, 2022
Nacuity Pharmaceuticals Inc. and Arctic Therapeutics LLC have entered into an exclusive licensing agreement and strategic partnership for the development and commercialization of NPI-001 (N-acetylcysteine amide, NACA) in Iceland for the treatment of hereditary cystatin C amyloid angiopathy (HCCAA).
Read More
Neurology/Psychiatric

Coave works with IMN on gene therapies targeting protein degradation in neurodegenerative disorders

Sep. 14, 2022
Coave Therapeutics SA has entered into a collaboration with the Institute of Neurodegenerative Diseases (IMN), a joint research unit associating the University of Bordeaux and the French National Centre of Scientific Research (CNRS), to develop gene therapy programs targeting protein degradation in neurodegenerative disorders.
Read More
Previous 1 2 … 222 223 224 225 226 227 228 229 230 … 2803 2804 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 18, 2026.
  • DNA and genome editing illustration

    ASGCT 2026: Directed evolution in gene therapy

    BioWorld
    Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 19, 2026
  • Ebola virus particle

    Authorities work to quickly sequence Ebola species in latest outbreak

    BioWorld
    If the recent hantavirus outbreak wasn’t enough to keep public health officials busy, a new Ebola virus disease outbreak has been confirmed by authorities in the...
  • Two silhouettes with tangle, gear, spiral

    NTX-819, a novel mGlu7 NAM for psychiatric disorders

    BioWorld Science
    Increasing evidence supports metabotropic glutamate mGlu7 receptor as a promising target in psychiatric disorders. Neurosterix Pharma Sarl has presented data on...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing